{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Marhelava K"],"funding":["European Research Council","Ministry of Science and Higher Education | Narodowe Centrum Badań i Rozwoju (National Centre for Research and Development)","Narodowe Centrum Nauki (National Science Centre)"],"pagination":["1395-1411"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12133591"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(6)"],"pubmed_abstract":["CD19 CAR-T cells have established a new standard for relapsed/refractory B-cell malignancies. However, the treatment fails in 50% of patients, often due to CD19 antigen loss. Alternative immunotherapies targeting other antigens are being tested but show limited efficacy, especially in cases of lineage switching or loss of B-cell phenotype, highlighting the need for novel targets. Herein, we identified leukocyte-immunoglobulin-like-receptor-B1 (LILRB1, CD85j) as a novel target for CAR-T cells through cell surface proteomics on patient-derived samples of high-risk B-cell acute lymphoblastic leukemia (B-ALL). LILRB1, an immune inhibitory receptor, is normally expressed only on monocytes and B-cells. We observed stable LILRB1 expression in B-ALL and B-cell non-Hodgkin lymphoma (B-NHL), even af"],"journal":["Leukemia"],"pubmed_title":["LILRB1-directed CAR-T cells for the treatment of hematological malignancies."],"pmcid":["PMC12133591"],"funding_grant_id":["805038/STIMUNO/ERC-2018-STG","805038","NOR/POLNOR/ALTERCAR/0056/2019","2020/39/O/NZ6/01434","2023/49/B/NZ7/03915"],"pubmed_authors":["Lech-Maranda E","Leray T","Marhelava K","Krawczyk M","Walchli S","Baranowska I","Swiderska B","Pepek M","Sedek L","Slota L","Perkowski B","Forcados C","Inderberg EM","Fernandez-Fuentes N","Krzywdzinska A","Malinowska A","Villatoro A","Czerwik N","Menendez P","Firczuk M","Fidyt K","Winiarska M"],"additional_accession":[]},"is_claimable":false,"name":"LILRB1-directed CAR-T cells for the treatment of hematological malignancies.","description":"CD19 CAR-T cells have established a new standard for relapsed/refractory B-cell malignancies. However, the treatment fails in 50% of patients, often due to CD19 antigen loss. Alternative immunotherapies targeting other antigens are being tested but show limited efficacy, especially in cases of lineage switching or loss of B-cell phenotype, highlighting the need for novel targets. Herein, we identified leukocyte-immunoglobulin-like-receptor-B1 (LILRB1, CD85j) as a novel target for CAR-T cells through cell surface proteomics on patient-derived samples of high-risk B-cell acute lymphoblastic leukemia (B-ALL). LILRB1, an immune inhibitory receptor, is normally expressed only on monocytes and B-cells. We observed stable LILRB1 expression in B-ALL and B-cell non-Hodgkin lymphoma (B-NHL), even af","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-03T07:53:24.767Z","creation":"2026-04-26T03:10:31.399Z"},"accession":"S-EPMC12133591","cross_references":{"pubmed":["40186066"],"doi":["10.1038/s41375-025-02580-z"]}}